Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects

• Egile Nagusiak: Xixi Li (Egilea), Shunyao Zhu (Egilea), Ping Yin (Egilea), Shuangshuang Zhang (Egilea), Juewen Xu (Egilea), Qin Zhang (Egilea), Senlin Shi (Egilea), Ting Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Melanoma is one of the most common malignant tumors. The anti-PD-1 antibody is used for the treatment of metastatic melanoma. Treatment success is only 35-40% and a range of immune-related adverse reactions can occur. Combination of anti-PD1 antibody therapy with other oncology therapies has been at...